

## Adherium Opens North American Office in the Bay Area

*Location in San Mateo supports leadership in digital technology*

**Melbourne, Australia, 8 August 2016;** Adherium Limited (ASX: ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced the expansion of its corporate footprint with the opening of its newly-established offices in San Mateo, California. Adherium's San Francisco Bay Area office will serve as the Company's North American commercial hub led by James Hattersley, Senior Vice President Business Development, North America. This will accelerate Adherium's expansion in North America and is ideally situated to attract Silicon Valley's top talent in fields specific to Adherium's commercial and operational objectives.

Garth Sutherland, Group CEO of Adherium said today, "The San Mateo Office is a very important part of the continued international expansion of Adherium."



### ABOUT ADHERIUM

Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease. Adherium operates globally from bases in USA, Europe and Australasia.

Adherium is a provider of digital health solutions to patients, pharmaceutical companies, integrated delivery networks and contract research organisations. The Company's proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally.

The Smartinhaler™ platform has so far been used in more than 65 projects (clinical, device validation or other) and has been referenced in 56 peer reviewed journal articles. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets. Adherium and AstraZeneca (AZN) entered into a 10-year commercial product development and supply agreement in July 2015.

Smartinhaler™, SmartinhalerLive™, and others are among the trademarks of Adherium.

[www.adherium.com](http://www.adherium.com)

[www.smartinhaler.com](http://www.smartinhaler.com)

#### Enquiries:

##### At Adherium:

##### Corporate AU/NZ

Julia Chambers  
Head Corporate  
Development  
M: +64 27 807 8153  
E: [juliac@adherium.com](mailto:juliac@adherium.com)

##### North America

James Hattersley  
SVP Business Development  
M: +1 610 955 5886  
E: [jamesh@adherium.com](mailto:jamesh@adherium.com)

##### Europe

John Tarplee  
SVP Business Development  
M: +44 791 770 1846  
E: [john@adherium.com](mailto:john@adherium.com)

##### Media enquiries:

##### AU/NZ Media

Rudi Michelson  
Monsoon Communications  
D: +61 3 9620 3333  
E: [rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

##### US Media

Erich Sandoval  
Lazar Partners  
D: +1 213-908-6226  
E: [esandoval@lazarpartners.com](mailto:esandoval@lazarpartners.com)

For personal use only